ARL4C Regulates the Progression of Clear Cell Renal Cell Carcinoma by Affecting the Wnt/β-Catenin Signaling Pathway

Figure 8

As a key effector of the Wnt/β-Catenin signaling pathway, ARL4C regulates EMT in ccRCC. (a–c) Western blot of the expression of ARL4C, β-catenin, cyclin D1, and c-myc proteins in 786-O and ACHN cells after adding Wnt agonist 1. (d-f) 786-O and ACHN cells were cultured with and without Wnt agonist 1 (Wnt agonist 1+/−), and ARL4C was then knocked down or not knocked down again (si-ARL4C/si-NC), followed by western blotting to determine the expression of ARL4C and β-catenin. (g-i) Expression of ARL4C, Wnt pathway-related proteins (β-catenin, cyclin D1, and c-myc), and EMT-related proteins (E-cadherin, N-cadherin, and vimentin) following knockdown of ARL4C in 786-O and ACHN cells. The above quantitative analysis of protein expression was normalized relative to β-actin levels. , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)